Fibroblast growth factor 23 production in bone is directly regulated by 1α,25-dihydroxyvitamin D, but not PTH

American Journal of Physiology - Renal Physiology

Volumn 299, Issue 5, 2010, Pages

  Saji, Fumie ^a   Shigematsu, Takashi ^a   Sakaguchi, Toshifumi ^a   Ohya, Masaki ^a   Orita, Hikari ^a   Maeda, Yuka ^a   Ooura, Maki ^a   Mima, Toru ^a   Negi, Shigeo ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Chronic kidney disease; Phosphate; Secondary hyperparathyroidism; Vitamin D receptor

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; MESSENGER RNA; PARATHYROID HORMONE; VITAMIN D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALVARIA; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; HORMONE ACTION; KIDNEY FAILURE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UREMIA;

EID: 78349288025     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00169.2010     Document Type: Article

References (40)

1. Alos N, Ecarot B. Downregulation of osteoblast Phex expression by PTH. Bone 37: 589-598, 2005.
2. 3. Am J Physiol Renal Physiol 286: F739-F748, 2004.
3. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study. J Am Soc Nephrol 18: 2601-2608, 2007. (Pubitemid 47378877)
4. Fukagawa M, Kazama JJ. With or without the kidney: the role of FGF23 in CKD. Nephrol Dial Transplant 20: 1295-1298, 2005.
5. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92: 1436-1443, 1993.
6. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592, 2008.
7. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 65: 1943-1946, 2004.
8. Inoue Y, Segawa H, Kaneko I, Yamanaka S, Kusano K, Kawakami E, Furutani J, Ito M, Kawahata M, Saito H, Fukushima N, Kato S, Kanayama H, Miyamoto K. Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem J 390: 325-331, 2005.
9. Ito M, Sakai Y, Furumoto M, Segawa H, Haito S, Yamanaka S, Nakamura R, Kuwahata M, Miyamoto K. Vitamin D and phosphate regulate fibroblast growth factor-23 in K-672 cells. Am J Physiol Renal Physiol 288: F2543-F2549, 2005.
10. Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, Nishizawa Y. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary heperparathyroidism. J Am Soc Nephrol 18: 2683-2688, 2007.
11. 3 upregulates FGF23 gene expression in bone: the final link an a renal-gastrointestinal- skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289: G1036-G1042, 2005.
12. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272-2279, 2003.
13. Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V, Manor E, Buriakovsky S, Hadad Y, Goding J, Parvari R. Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 86: 273-278, 2010.
14. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD. Regulation of fibroblast growth factor 23 expression but not degradation by PHEX. J Biol Chem 278: 37419-37426, 2003. (Pubitemid 37175262)
15. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17: 1305-1315, 2006.
16. Liu S, Tang W, Zhou J, Vierthaler L, Quarles LD. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am J Physiol Endocrinol Metab 293: E1636-E1644, 2007.
17. Liu S, Zhou J, Tang W, Menard R, Feng JQ, Quarles LD. Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endocrinol Metab 295: E254-E261, 2008.
18. Llach F, Velasquez FF. Secondary hyperparathyroidism in chronic renal failure. Pathogenic and clinical aspects. Am J Kidney Dis 38: S20-S33, 2001.
19. Lorenz-Depiereux B, Schnabel D, Tiosano D, Hausler G, Tim Strom TM M. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 86: 267-272, 2010.
20. Mirams M, Robinson BG, Mason RS, Nelson AE. Bone as a source of FGF23: regulation by phosphate? Bone 35: 1192-1199, 2004.
21. Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, Wada M. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 69: 531-537, 2006.
22. Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 67: 1171-1178, 2005. (Pubitemid 41623344)
23. 3 in the parathyroid in vivo. J Clin Invest 86: 1968-1975, 1990.
24. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, Shuto E, Nashiki K, Arai H, Yamamoto H, Takeda E. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 70: 2141-2147, 2006.
25. Perwad F, Azam N, Zhang MYH, Yamashita T, Tenenhouse HS, Portale AA. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146: 5358-5364, 2005.
26. Perwad F, Zhang MYH, Tenenhouse HS, Portale A. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1α-hydroxylase expression in vitro. Am J Physiol Renal Physiol 293: F1577-F1583, 2007.
27. 3 and phosphorus in vivo. J Biol Chem 280: 2543-2549, 2005.
28. Saji F, Shiizaki K, Shimada S, Okada T, Kunimoto K, Sakaguchi T, Hatamura I, Shigematsu T. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron Physiol 111: 61-68, 2009.
29. Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Uchida K, Nakanishi S, Kazama JJ, Gejyo F, Yamashita T, Fukagawa M. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 44: 481-487, 2004. (Pubitemid 39164625)
30. Shigematsu T, Kazama J, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M. Possible involvement of circulating fibroblast growth factor 23 in development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44: 250-256, 2004. (Pubitemid 38962552)
31. Shiizaki K, Negi S, Hatamura I, Sakaguchi T, Saji F, Kunimoto K, Mizobuchi M, Imazeki I, Ooshima A, Akizawa T. Biochemical and cellular effects of direct maxacalcitol injection into parathyroid gland in uremic rats. J Am Soc Nephrol 16: 97-108, 2005.
32. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435, 2004.
33. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561-568, 2004.
34. Silver J, Kilav R, Naveh-Many T. Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Physiol 283: F367-F376, 2002.
35. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 78: 1296-1301, 1986.
36. Slatopolsky E, Dusso A, Brown AJ. The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure. Am J Med Sci 317: 370-376, 1999.
37. Sullivan W, Carpenter T, Glorieux F, Travers R, Insogna K. A prospective trial of phosphate and 1,25-dihydroxyvatmin D3 therapy in symptomatic adults with X-linked hypophophatemic rickets. J Clin Endocrinol Metab 75: 879-885, 1992.
38. Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Shaney S, Gales B, Juppner H, Salusky IB. Relationship between plasma FGF-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 94: 511-517, 2009.
39. Yamaguchi M, Oishi H, Suketa Y. Zinc stimulation of bone protein synthesis in tissue culture: activation of aminoacyl-tRNA synthetase. Biochem Pharm 37: 4075-4080, 1998.
40. Yu X, Sabbagh Y, Davis SI, Demay MB, White KE. Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 36: 971-977, 2005.